Bactericidal activities of meropenem and ertapenem against extended-spectrum-β-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model

Antimicrobial Agents and Chemotherapy

Volumn 51, Issue 4, 2007, Pages 1481-1486

  DeRyke, C Andrew ^a   Banevicius, Mary Anne ^a   Fan, Hong Wei ^a,b   Nicolau, David P ^a  

^a HARTFORD HOSPITAL   (United States)

^b PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ERTAPENEM; EXTENDED SPECTRUM BETA LACTAMASE; MEROPENEM;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL INFECTION; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATE; COLONY FORMING UNIT; CONTROLLED STUDY; DISEASE MODEL; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; ESCHERICHIA COLI; FEMALE; KLEBSIELLA PNEUMONIAE; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NEUTROPENIA; NONHUMAN; PRIORITY JOURNAL; THIGH;

ANIMALS; BETA-LACTAMASES; BETA-LACTAMS; DISEASE MODELS, ANIMAL; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE; MICE; MICROBIAL SENSITIVITY TESTS; THIENAMYCINS;

EID: 34247142710     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.00752-06     Document Type: Article

References (35)

1. Andes, D., and W. A. Craig. 2001. Impact of extended-spectrum beta-lactamase production on the activity of cefepime in a murine-thigh infection model, abstr. 1099. Abstr. 41st Intersci. Conf. Antimicrob. Agents Chemother. American Society for Microbiology, Washington, DC.
2. Andes, D., and W. A. Craig. 1998. In vivo activities of amoxicillin and amoxicillin-clavulanate against Streptococcus pneumoniae: application to breakpoint determinations. Antimicrob. Agents Chemother. 42:2375-2379.
3. Clinical and Laboratory Standards Institute. 2006. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard, 7th ed. CLSI document M7-A7. Clinical and Laboratory Standards Institute, Wayne, PA.
4. Craig, W. A. 1998. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin. Infect. Dis. 26:1-10.
5. Craig, W. A., S. M. Bhavnani, and P. G. Ambrose. 2004. The inoculum effect: fact or artifact? Diagn. Microbiol. Infect. Dis. 50:229-230.
6. Dandekar, P. K., R. Quintiliani, C. H. Nightingale, and D. P. Nicolau. 2002. Extended-spectrum beta-lactamases (ESBL). Conn. Med. 66:13-15.
7. DeRyke, C. A., and D. P. Nicolau. 2007. Is all free time above the minimum inhibitory concentration the same: implications for beta-lactam in vivo modeling. Int. J. Antimicrob. Agents 29:341-343.
8. Dreetz, M., J. Hamacher, J. Eller, K. Borner, P. Koeppe, T. Schaberg, and H. Lode. 1996. Serum bactericidal activities and comparative pharmacokinetics of meropenem and imipenem-cilastatin. Antimicrob. Agents Chemother. 40:105-109.
9. Drusano, G. L. 2003. Prevention of resistance: a goal for dose selection for antimicrobial agents. Clin. Infect. Dis. 36:S42-S50.
10. Elkhaili, H., S. Niedergang, D. Pompei, L. Linger, D. Leveque, and F. Jehl. 1996. High-performance liquid chromatographic assay for meropenem in serum. J. Chromatogr. B 686:19-26.
11. Goossens, H., and B. Grabein. 2005. Prevalence and antimicrobial susceptibility data for extended-spectrum beta-lactamase- and AmpC-producing Enterobacteriaceae from the MYSTIC program in Europe and the United States (1997-2004). Diagn. Microbiol. Infect. Dis. 53:257-264.
12. Joly-Guillou, M. L., M. Wolff, J. J. Pocidalo, F. Walker, and C. Carbon. 1997. Use of a new mouse model of Acinetobacter baumannii pneumonia to evaluate the postantibiotic effect of imipenem. Antimicrob. Agents Chemother. 41:345-351.
13. Jones, R. N., D. J. Biedenbach, and A. C. Gales. 2003. Sustained activity and spectrum of selected extended-spectrum beta-lactams (carbapenems and cefepime) against Enterobacter spp. and ESBL-producing Klebsiella spp.: report from the SENTRY antimicrobial surveillance program (USA, 1997-2000). Int. J. Antimicrob. Agents 21:1-7.
14. Jones, R. N., and M. A. Pfaller. 2003. Antimicrobial activity against strains of Escherichia coli and Klebsiella spp. with resistance phenotypes consistent with an extended-spectrum beta-lactamase in Europe. Clin. Microbiol. Infect. 9:708-712.
15. Jones, R. N., M. A. Pfaller, G. V. Doern, M. E. Erwin, R. J. Hollis, et al. 1998. Antimicrobial activity and spectrum investigation of eight broad-spectrum beta-lactam drugs: a 1997 surveillance trial in 102 medical centers in the United States. Diagn. Microbiol. Infect. Dis. 30:215-228.
16. Jones, R. N., H. S. Sader, and T. R. Fritsche. 2005. Comparative activity of doripenem and three other carbapenems tested against Gram-negative bacilli with various beta-lactamase resistance mechanisms. Diagn. Microbiol. Infect. Dis. 52:71-74.
17. Kohler, J., K. L. Dorso, K. Young, G. G. Hammond, H. Rosen, H. Kropp, and L. L. Silver. 1999. In vitro activities of the potent, broad-spectrum carbapenem MK-0826 (L-749,345) against broad-spectrum β-lactamase- and extended-spectrum β-lactamase-producing Klebsiella pneumoniae and Escherichia coli clinical isolates. Antimicrob. Agents Chemother. 43:1170-1176.
18. Lautenbach, E., J. B. Patel, W. B. Bilker, P. H. Edelstein, and N. O. Fishman. 2001. Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for infection and impact of resistance on outcomes. Clin. Infect. Dis. 32:1162-1171.
19. Livermore, D. M., K. J. Oakton, M. W. Carter, and M. Warner. 2001. Activity of ertapenem (MK-0826) versus Enterobacteriaceae with potent beta-lactamases. Antimicrob. Agents Chemother. 45:2831-2837.
20. Maglio, D., M. A. Banevicius, C. Sutherland, C. Babalola, C. H. Nightingale, and D. P. Nicolau. 2005. Pharmacodynamic profile of ertapenem against Klebsiella pneumoniae and Escherichia coli in a murine thigh model. Antimicrob. Agents Chemother. 49:276-280.
21. Maglio, D., C. Ong, M. A. Banevicius, Q. Geng, C. H. Nightingale, and D. P. Nicolau. 2004. Determination of the in vivo pharmacodynamic profile of cefepime against extended-spectrum-beta-lactamase-producing Escherichia coli at various inocula. Antimicrob. Agents Chemother. 48:1941-1947.
22. Mattie, H., L. C. Zhang, E. van Strijen, B. R. Sekh, and A. E. Douwes-Idema. 1997. Pharmacokinetic and pharmacodynamic models of the antistaphylococcal effects of meropenem and cloxacillin in vitro and in experimental infection. Antimicrob. Agents Chemother. 41:2083-2088.
23. Mattoes, H. M., J. L. Kuti, G. L. Drusano, and D. P. Nicolau. 2004. Optimizing antimicrobial pharmacodynamics: dosage strategies for meropenem. Clin. Ther. 26:1187-1198.
24. Moczygemba, L. R., C. R. Frei, and D. S. Burgess. 2004. Pharmacodynamic modeling of carbapenems and fluoroquinolones against bacteria that produce extended-spectrum beta-lactamases. Clin. Ther. 26:1800-1807.
25. Musson, D. G., A. Majumdar, S. Holland, K. Birk, L. Xi, G. Mistry, D. Sciberras, J. Muckow, P. Deutsch, and J. D. Rogers. 2004. Pharmacokinetics of total and unbound ertapenem in healthy elderly subjects. Antimicrob. Agents Chemother. 48:521-524.
26. Nix, D. E., A. K. Majumdar, and M. J. DiNubile. 2004. Pharmacokinetics and pharmacodynamics of ertapenem: an overview for clinicians. J. Antimicrob. Chemother. 53(Suppl. 2):ii23-ii28.
27. Ong, C. T., P. R. Tessier, C. Li, C. H. Nightingale, and D. P. Nicolau. 2007. Comparative in vivo efficacy of meropenem, imipenem, and cefepime against Pseudomonas aeruginosa expressing MexA-MexB-OprM efflux pumps. Diagn. Microbiol. Infect. Dis. 57:153-161.
28. Paterson, D. L., W. C. Ko, A. Von Gottberg, S. Mohapatra, J. M. Casellas, H. Goossens, L. Mulazimoglu, G. Trenholme, K. P. Klugman, R. A. Bonomo, L. B. Rice, M. M. Wagener, J. G. McCormack, and V. L. Yu. 2004. Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production of extended-spectrum beta-lactamases. Clin. Infect. Dis. 39:31-37.
29. Ramphal, R., and P. G. Ambrose. 2006. Extended-spectrum beta-lactamases and clinical outcomes: current data. Clin. Infect. Dis. 42(Suppl. 4):S164-S172.
30. Rhomberg, P. R., T. R. Fritsche, H. S. Sader, and R. N. Jones. 2005. Comparative antimicrobial potency of meropenem tested against Gram-negative bacilli: report from the MYSTIC surveillance program in the United States (2004). J. Chemother. 17:459-469.
31. Schwaber, M. J., S. Navon-Venezia, K. S. Kaye, R. Ben-Ami, D. Schwartz, and Y. Carmeli. 2006. Clinical and economic impact of bacteremia with extended-spectrum-beta-lactamase-producing Enterobacteriaceae. Antimicrob. Agents Chemother. 50:1257-1262.
32. Turnidge, J. D. 1998. The pharmacodynamics of beta-lactams. Clin. Infect. Dis. 27:10-22.
33. Walker, R., D. Andes, J. Conklin, S. Ebert, and W. A. Craig. 1994. Abstr. 34th Intersci. Conf. Antimicrob. Agents Chemother., abstr. A91.
34. Wexler, H. M. 2004. In vitro activity of ertapenem: review of recent studies. J. Antimicrob. Chemother. 53(Suppl. 2):ii11-ii21.
35. Xuan, D., M. Banevicius, B. Capitano, M. K. Kim, C. Nightingale, and D. Nicolau. 2002. Pharmacodynamic assessment of ertapenem (MK-0826) against Streptococcus pneumoniae in a murine neutropenic thigh infection model. Antimicrob. Agents Chemother. 46:2990-2995.